Connect Biopharma Holdings (CNTB) Change in Account Payables (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Change in Account Payables for 3 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Account Payables rose 393.05% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 678.79% YoY) and the FY2025 annual result came in at $1.6 million, up 186.88% from the prior year.
• Change in Account Payables advanced to $2.3 million in Q1 2026 per CNTB's latest filing, from -$30000.0 in the prior quarter.
• Over the last five years, Change in Account Payables for CNTB reached as high as $2.3 million in Q1 2026 and fell as low as -$1.8 million in Q1 2024.
• A 3-year average of $233000.0 and a median of -$30000.0 in 2025 frame the typical range for Change in Account Payables.
• The largest YoY upside for Change in Account Payables was 817.39% in 2025 against a maximum downside of 104.08% in 2025.
• Year by year, Change in Account Payables stood at -$41000.0 in 2024, then grew by 26.83% to -$30000.0 in 2025, then soared by 7906.67% to $2.3 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $2.3 million, -$30000.0, and -$300000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.